| Blake V Fausett, MD | |
|
2550 Willakenzie Rd, Eugene, OR 97401-7865 | |
| (541) 434-0922 | |
| Not Available |
| Full Name | Blake V Fausett |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 15 Years |
| Location | 2550 Willakenzie Rd, Eugene, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043449481 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| John H Hunts Md Phd Llc | 3375604200 | 2 |
News Archive
Alexion Pharmaceuticals, Inc. announced that it has purchased patents and assets from Germany-based Orphatec Pharmaceuticals GmbH related to an investigational therapy for patients with molybdenum cofactor deficiency (MoCD) Type A, a devastating ultra-rare genetic disorder characterized by severe brain damage and rapid death in newborns.
AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.
The Washington Post Fact Checker assesses the Texas senator's TV ads that seek to drum up support for defunding the health law, while in some southern campaigns, some Democrats hope to portray their opponents as ideologically opposed to progress on issues such as health care.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.
› Verified 9 days ago
| Entity Name | John H Hunts Md Phd Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053556019 PECOS PAC ID: 3375604200 Enrollment ID: O20081210000268 |
News Archive
Alexion Pharmaceuticals, Inc. announced that it has purchased patents and assets from Germany-based Orphatec Pharmaceuticals GmbH related to an investigational therapy for patients with molybdenum cofactor deficiency (MoCD) Type A, a devastating ultra-rare genetic disorder characterized by severe brain damage and rapid death in newborns.
AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.
The Washington Post Fact Checker assesses the Texas senator's TV ads that seek to drum up support for defunding the health law, while in some southern campaigns, some Democrats hope to portray their opponents as ideologically opposed to progress on issues such as health care.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Blake V Fausett, MD 2550 Willakenzie Rd, Eugene, OR 97401-7865 Ph: (541) 434-0922 | Blake V Fausett, MD 2550 Willakenzie Rd, Eugene, OR 97401-7865 Ph: (541) 434-0922 |
News Archive
Alexion Pharmaceuticals, Inc. announced that it has purchased patents and assets from Germany-based Orphatec Pharmaceuticals GmbH related to an investigational therapy for patients with molybdenum cofactor deficiency (MoCD) Type A, a devastating ultra-rare genetic disorder characterized by severe brain damage and rapid death in newborns.
AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.
The Washington Post Fact Checker assesses the Texas senator's TV ads that seek to drum up support for defunding the health law, while in some southern campaigns, some Democrats hope to portray their opponents as ideologically opposed to progress on issues such as health care.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.
› Verified 9 days ago
Scott Cherne, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1125 Darlene Ln, Suite 100, Eugene, OR 97401 Phone: 541-343-5000 Fax: 541-344-9478 | |
Walter Benjamin Kunz, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1550 Oak St, Suite 7, Eugene, OR 97401 Phone: 541-687-1927 | |
Dr. Anthony Grillo, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1125 Darlene Ln, Eugene, OR 97401 Phone: 541-343-5000 | |
Peter Wyzinski, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1125 Darlene Ln, Suite 100, Eugene, OR 97401 Phone: 541-343-5000 Fax: 541-344-9478 | |
Mr. Allan Armstrong Hunter Iii, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 360 S Garden Way Ste 101a, Eugene, OR 97401 Phone: 541-237-8400 Fax: 541-237-8850 | |
Matthew D Neale, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 992 Country Club Rd, Ste101, Eugene, OR 97401 Phone: 541-687-1715 Fax: 541-687-1690 |